Bisphosphonates, cancer, and osteonecrosis--a single practice experience

Abstract

Intravenous bisphosphonates have come into increasing use to protect cancer patients from adverse boney events. The prevalence of use, demographics of a treatment population, and occurrence of a particular side effect are explored in this article.